Revalesio
Revalesio is a clinical-stage pharmaceutical company developing RNS60, a proprietary oxygen-supersaturated saline therapeutic that targets mitochondrial dysfunction to treat acute ischemic stroke (lead Phase 3 program), ALS, and discovery-stage neurological indications including Alzheimer's, Parkinson's, and traumatic brain injury.
- Company typePrivate
- Founded2007
- HeadquartersTacoma, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Revalesio does
Revalesio is a clinical-stage pharmaceutical company headquartered in Tacoma, Washington, developing RNS60, a proprietary oxygen-supersaturated saline therapeutic that targets mitochondrial dysfunction to restore cellular vitality across neurological conditions. The company's platform applies Taylor-Couette-Poiseuille (TCP) flow, a fluid physics process, to generate charge-stabilized nanostructures (CSNs) — oxygen supersaturated in saline — that demonstrate cytoprotective, anti-inflammatory, and mitochondrial-supportive properties when delivered intravenously. Revalesio operates its own cGMP-compliant manufacturing facility in Tacoma for RNS60 production.
The company's lead clinical program is RNS60 as an adjunctive IV therapy for acute ischemic stroke patients undergoing endovascular thrombectomy. The Phase 2 RESCUE trial demonstrated a 50% reduction in infarct growth, improved functional independence (72% mRS 0–2 vs 37% placebo at Day 90), and 4.8 days earlier hospital discharge, supporting progression to the planned Phase 3 RESTORE trial. A second completed Phase 2 program in ALS (147 patients, 22 Italian sites) showed a 6-month median survival extension. Additional discovery-stage programs target Alzheimer's disease, Parkinson's disease, traumatic brain injury, and age-related neurodegeneration. RNS60 has been administered to 400+ patients with a strong safety profile and holds FDA Fast Track designation for both stroke and ALS, plus Orphan Drug Designation for ALS.
Revalesio is pre-revenue and monetizes only through potential future commercialization or licensing. Its go-to-market plan is hospital-channel IV infusion administered adjunctively with endovascular thrombectomy. Distribution will be through specialty/hospital pharmacy channels upon FDA approval. The company has retained Torreya Partners for business development activities, indicating a likely licensing or partnership pathway to fund late-stage development and commercialization. The leadership team includes senior pharma veterans from Eli Lilly (Executive Chairman, VP Finance), Amgen/Immunex (VP Drug Development), and a CMO with 17 prior FDA approvals.
Revalesio firmographics
Firmographics- Name
- Revalesio
- Legal name
- Revalesio Corporation
- Website
- https://revalesio.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Revalesio is a clinical-stage pharmaceutical company developing RNS60, a proprietary oxygen-supersaturated saline therapeutic that targets mitochondrial dysfunction to treat acute ischemic stroke (lead Phase 3 program), ALS, and discovery-stage neurological indications including Alzheimer's, Parkinson's, and traumatic brain injury.
- Ownership category
- akta.pro rank
Revalesio industry classification
Industry- Product category
- Clinical-Stage Neuroprotective Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Stroke & Vascular Neurology (HLAKAIAG)
- akta.pro secondary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Revalesio is headquartered
LocationHeadquarters
- HQ city
- Tacoma
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Revalesio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Development: Pre-revenue clinical-stage pharmaceutical company. RNS60 is an investigational drug not yet approved for commercial sale. Revenue will be generated upon successful FDA approval and commercialization of RNS60 for acute ischemic stroke and potentially other neurological indications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Revalesio product offering
Product offeringCore offering
Revalesio develops RNS60, a proprietary oxygen-supersaturated saline therapeutic produced via a Taylor-Couette-Poiseuille fluid physics process that creates charge-stabilized nanostructures. The lead clinical indication is acute ischemic stroke (Phase 2 RESCUE complete, Phase 3 RESTORE in preparation), with Phase 2 results showing a 50% reduction in brain tissue loss. The pipeline also includes ALS (Phase 2 complete with FDA Orphan Drug and Fast Track designations) and discovery-stage programs for Alzheimer's, Parkinson's, traumatic brain injury, and age-related neurodegeneration.
Product overview
Revalesio is a clinical-stage pharmaceutical company developing RNS60, a proprietary oxygen-supersaturated saline therapeutic that uniquely targets mitochondrial dysfunction to restore cellular vitality. The core product RNS60 is being developed across multiple clinical programs: the lead indication is acute ischemic stroke (Phase 2 completed, Phase 3 RESTORE trial planned), with additional programs in ALS (Phase 2 completed) and discovery-stage programs for Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, and Age-Related Neurodegeneration. The technology platform utilizes Taylor-Couette-Poiseuille (TCP) flow to generate therapeutics from biologically active dissolved gases delivered via IV infusions.
Differentiator
Problem solved
Functional benefit
Products and services
- RNS60 (Oxygen-Supersaturated Saline) RNS60 is a proprietary, oxygen-enriched saline (sodium chloride solution supersaturated with medical-grade oxygen) produced via Taylor-Couette-Poiseuille flow to generate charge-stabilized nanostructures. It has demonstrated cytoprotective, anti-inflammatory, and mitochondrial-supportive properties and is being developed as an adjunctive therapy for acute ischemic stroke and other neurological conditions including ALS and Alzheimer's disease.
- RNS60 for Acute Ischemic Stroke RNS60 is being developed as an adjunctive IV treatment for acute ischemic stroke patients undergoing endovascular thrombectomy, intended to protect brain tissue beyond reperfusion. The Phase 2 RESCUE trial met primary endpoints with a 50% reduction in infarct growth and improved functional outcomes, and Phase 3 RESTORE is in preparation.
- RNS60 for Amyotrophic Lateral Sclerosis (ALS) RNS60 is being developed for ALS (Lou Gehrig's disease), a fatal motor-neuron disorder. Phase 2 trials showed significantly slower decline in respiratory function and a 6-month extension of median survival versus placebo, and the program holds FDA Orphan Drug and Fast Track designations.
- RNS60 Discovery Program - Traumatic Brain Injury Exploratory research program investigating how protecting mitochondria with RNS60 can reduce brain loss and improve outcomes in traumatic brain injury.
- RNS60 Discovery Program - Alzheimer's Disease Exploratory research program investigating RNS60's potential to treat Alzheimer's disease and other dementias by protecting neuronal function, restoring neuronal connections, and promoting neuronal plasticity.
- RNS60 Discovery Program - Parkinson's Disease Exploratory research program investigating RNS60's potential for Parkinson's disease treatment through neuroprotection and mitochondrial support.
- RNS60 Discovery Program - Age-Related Neurodegeneration Exploratory research program investigating RNS60's potential to combat progressive decline in neurodegenerative diseases and aging through mitochondrial protection.
Quantifiable outcome
- 50% reduction in brain tissue loss (p<0.05) in stroke patients treated with high-dose RNS60 vs placebo
- +6 more outcomes
Companies that use Revalesio
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles3 records
Revalesio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Revalesio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Rhode Island Hospital Comprehensive Stroke CentercoreLead clinical site for Phase 2 RESCUE trial evaluating RNS60 in acute ischemic stroke patients undergoing endovascular thrombectomy. Principal Investigator Dr. Ryan McTaggart led trial design and execution across 5 U.S. sites.
- Mario Negri Institute for Pharmacological ResearchcoreConducted Phase 2 clinical trial evaluating RNS60 in 147 ALS patients across 22 Italian clinical centers. Sponsored placebo-controlled, randomized, double-blind trial partially funded by ALS Association. Results showed RNS60 significantly slowed decline of forced vital capacity and extended survival by 6 months.
- Sean M. Healey & AMG Center at Massachusetts General HospitalcoreCollaborated on Healey ALS Platform Trial, the first platform trial for ALS testing multiple treatments simultaneously to accelerate therapy development. RNS60 was selected for entry into the trial by expert ALS scientists and Healey Center Science Advisory Committee.
- Northeast ALS Consortium (NEALS)coreClinical trial consortium providing infrastructure for multicenter Phase II ALS trial. Collaborated with Mario Negri Institute and MGH on trial design and execution across 22 Italian centers and MGH in the U.S.
- Torreya PartnersminorRetained for business development activities including licensing and partnering discussions for RNS60. Global investment banking boutique serving life sciences companies.
- McGill UniversitycoreCollaborative research showing RNS60 promotes myelination by oligodendrocytes and protects myelin-producing cells. Published in Scientific Reports. Demonstrated potential therapeutic application in multiple sclerosis and other demyelinating diseases.
- Rush University Medical CentercoreCollaborative research demonstrating RNS60 potential for treating Alzheimer's disease and other dementias by protecting neuronal function, restoring neuronal connections, and promoting neuronal plasticity. Published findings in PLOS ONE.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Revalesio competitors and assessment
Company assessmentDirect peers
- Abliva: Clinical-stage biotech developing therapeutics for primary mitochondrial diseases, with mechanisms targeting cellular energy metabolism. Directly comparable to Revalesio because both focus on small-molecule/biologic modulation of mitochondrial function for neurological indications — Abliva (KL1333) and Revalesio (RNS60) target the same bioenergetic axis underlying rare and neurological disease.
- Khondrion: Clinical-stage biotech developing sonlicromanol and other mitochondrial-targeted therapeutics for mitochondrial diseases and neurodegenerative conditions. Comparable to Revalesio because both pursue mitochondrial pharmacology to address bioenergetic failure, sharing scientific lineage in the same mechanism space (redox modulation, mitochondrial preservation) that Revalesio targets with RNS60.
- ProJenX (previously Project ALS): Clinical-stage biotech developing therapeutics for ALS and neurodegenerative diseases, with lead assets targeting neuroprotection and motor neuron preservation. Directly comparable to Revalesio because both target ALS via non-standard mechanisms (mitochondrial and neuroinflammatory modulation) and compete for the same KOL and patient attention.
- Athersys / Veloxis Holdings: Clinical-stage company developing MultiStem cell therapy for ischemic stroke and ARDS, having pursued Phase 3 development in stroke. Comparable to Revalesio as a direct clinical-stage stroke neuroprotection peer addressing the same unmet need (adjunctive therapy in acute ischemic stroke) where Big Pharma has historically underinvested.
- ZZ Biotech: Clinical-stage biotech developing 3K3A-APC, a neuroprotective biologic for ischemic stroke and intracerebral hemorrhage. Comparable to Revalesio because both pursue an adjunctive neuroprotection approach in acute stroke, targeting biological pathways (PAR signaling vs mitochondrial preservation) that seek to limit brain tissue loss beyond reperfusion.
Broad incumbents
- Biogen: Large biopharma with a major ALS franchise (Spinraza, Qalsody) and broad neuro pipeline (MS, Alzheimer's, Parkinson's). Compares to Revalesio as the dominant neurology incumbent competing for the same physicians, payers, and patient populations that RNS60 targets, particularly in ALS where Biogen's commercial infrastructure would directly threaten RNS60's launch economics.
- Roche: Large biopharma with neurology pipeline presence (evrysdi, Ocrevus, late-stage ALS and stroke programs in-licensed from smaller players). Broadly comparable to Revalesio as a deep-pocketed neurology incumbent with the ability to acquire similar assets or directly compete with RNS60 in the stroke intervention space.
Emerging players
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration (ALS/FTD, Parkinson's, Alzheimer's, Hunter syndrome) with programs including small molecules and biologics addressing lysosomal function and neuroinflammation. Comparable to Revalesio as a high-profile emerging neuro player pursuing multiple neurological indications with non-standard mechanisms.
- ReNetX Neuro: Clinical-stage biotech developing therapeutics for spinal cord injury and stroke based on Nogo receptor decoy protein (e.g., AXER-204). Comparable to Revalesio as a smaller neuro-repair peer targeting CNS injury with a biologic approach, seeking the same KOL network and competing for stroke clinical-site resources.
- Helixmith (formerly VM BioPharma): Clinical-stage gene therapy company (Engineered DNA-based medicines) focused on peripheral neuropathy, diabetic neuropathy and ALS via plasmid DNA encoding neurotrophic factors. Comparable to Revalesio as an emerging player pursuing novel modality treatments for neurology indications including ALS, where both compete for the same underserved market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Revalesio social profiles
Digital presenceRevalesio compliance and trust
Trust signalCompliance3 records
Revalesio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Revalesio leadership team
Management profileNumber of profiles
Profiles9 records
Revalesio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Revalesio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Revalesio
What does Revalesio do?
Revalesio develops RNS60, a proprietary oxygen-supersaturated saline therapeutic produced via a Taylor-Couette-Poiseuille fluid physics process that creates charge-stabilized nanostructures. The lead clinical indication is acute ischemic stroke (Phase 2 RESCUE complete, Phase 3 RESTORE in preparation), with Phase 2 results showing a 50% reduction in brain tissue loss. The pipeline also includes ALS (Phase 2 complete with FDA Orphan Drug and Fast Track designations) and discovery-stage programs for Alzheimer's, Parkinson's, traumatic brain injury, and age-related neurodegeneration.
Is Revalesio a public or private company?
Revalesio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Revalesio founded?
Revalesio was founded in 2007. It employs 11 to 50 people.
Where is Revalesio based?
Revalesio is headquartered in Tacoma, United States, in the North America region.
How does Revalesio make money?
One revenue line is on record: pharmaceutical Development.
Who are Revalesio's main competitors?
Direct peers on record are Abliva, Khondrion, ProJenX (previously Project ALS), Athersys / Veloxis Holdings and ZZ Biotech. Broad incumbents are Biogen and Roche. Emerging players are Denali Therapeutics, ReNetX Neuro and Helixmith (formerly VM BioPharma).
Does Revalesio have an API?
No public API is recorded for Revalesio.
What industry is Revalesio in?
Revalesio's product category is Clinical-Stage Neuroprotective Pharmaceuticals. Its primary akta.pro industry code is HLAKAIAG, Stroke & Vascular Neurology, with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 541714.